Antiemetic Combinations

PreclinicalSmall molecule

Antiemetic Combinations is one of 8 small molecule programs targeting Hyperemesis Gravidarum. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hyperemesis GravidarumActive, not recruiting

Hyperemesis GravidarumPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Hyperemesis Gravidarum

#DrugCompanyPhaseTrials

Catapres

Boehringer Ingelheim

Phase 3

1 2

Zofran

Novartis

Phase 2

1 3

Thiamine

UUniversiti Kebangsaan Malaysia Medical Centre

Remeron

1 5

Reglan

IIstituto Clinico Humanitas

Phase 2

1 6

Neurontin

VViatris Specialty LLC

Phase 2

1 7

Glucophage

EMD Serono

Phase 2

1 8

Antiemetic Combinations

TTasnem Abo-elouon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperemesis Gravidarum1 trial

Use of the Modified PUQE Score on Admitted Cases of Hyperemesis Gravidarum (HG) to Guide Response to Treatment

Completed·TTasnem Abo-elouon··NCT04785911·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antiemetic Combinations. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antiemetic Combinations compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antiemetic Combinations. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tasnem Abo-elouon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTasnem Abo-elouon

Antiemetic Combinations

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperemesis Gravidarum1 trial

References

Drug Info

Quick Facts

Related News